CSN Login
Members Online: 2

You are here

Tecentriq to treat triple-negative breast cancer

Date: 
Wednesday, March 13, 2019 - 1:00pm
Your announcement.: 

My name is MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.

The Canadian government will soon be reviewing the use of Tecentriq to treat triple-negative breast cancer and Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.


Does this survey apply to you?

We are looking for woman with triple-negative breast cancer and women who have been treated with Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) to talk about their treatment experience.
YOU DO NOT NEED TO LIVE IN CANADA TO PARTICIPATE.

If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/tecentriqsurvey

If you would like to speak with us directly about your cancer or treatment experience, you can contact Shawna Rich-Ginsberg at shawna@rethinkbreastcancer.com.

MJ DeCoteau
Founder + Executive Director
Rethink Breast Cancer

 

Check the appropriate category for your announcement: 
Research study, clinical trial, focus group,etc (Requires IRB review and certification. See here for guidelines.)
Contact - Email: 
shawna@rethinkbreastcancer.com
Contact - First name: 
Shawna
Contact - Last name: 
Rich-Ginsberg
Contact - Telephone number: 
416-220-0700
Subscribe to Comments for "Tecentriq to treat triple-negative breast cancer "